VBLT - Vascular Biogenics: A Buy On Promising Cancer Therapy
Vascular Biogenics (VBLT), which operates as VBL Therapeutics, is a clinical stage pharmaceutical company focused on cancer therapies. Its lead program, VB-111 for glioblastoma (brain cancer), failed to produce positive Phase 3 results in 2018, resulting in a collapse of the company's stock price. The company and outside experts believe this is likely because of a change in the regimen used following a successful Phase 2 trial. VB-111 is in a Phase 3 trial for platinum-resistant ovarian cancer, following positive Phase 2 trials. I believe there is a very good chance that VB-111 will prove